QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Qiagen N.V.

QIAGEN is a self-described leading provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research.

QIAGEN

OEM by QIAGEN

QIAGEN Life Sciences

QIAGEN Brasil

QIAGEN Digital Insights

QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life.

Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. 

QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). 

As of December 31 2021 QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at www.qiagen.com.

Ingenium Pharmaceuticals AG

ArcherDX

Xagenic

Protagen

Exosome Diagnostics

Coley Pharmaceutical Group

U.S. Department of Defense

U.S. Department of Health & Human Services

We are thrilled to launch new QIAcuity dPCR assays for microbial applications to target a wide range of pathogens responsible for tropical diseases, sexually transmitted infections, and urinary tract infections. Learn more 👉 https://lnkd.in/ewKVwqqd
 
✅ 35 new wet-lab tested digital PCR Microbial DNA Detection Assays on the research platform GeneGlobe target a wide range of pathogens causing tropical diseases, sexually transmitted and urinary tract infections.
 
✅ QIAcuity digital PCR technology enables precise and sensitive detection of pathogens, supporting infectious disease research and public health efforts.
 
✅ New assays add to our comprehensive portfolio for microbial research showcased at the ASM Microbe conference from June 13–17.

🩺 Patients with infectious illnesses often have signs and symptoms that are indicative of a disease but aren't specific enough to clinically distinguish what makes them ill. These patients are frequently given broad treatment, heavy monitoring and possibly unnecessary interventions. This puts a burden on healthcare systems, clinical labs and clinicians, and means patients aren't getting the best care possible.
 
😊 With syndromic testing, we can quickly survey many different pathogens in a single patient sample, helping clinicians identify the pathogen responsible. So they can make faster clinical decisions and give patients get better care, faster.
 
Learn more about rapid diagnostics with syndromic testing here: https://lnkd.in/gv2aGQ7N

🏳‍🌈 At QIAGEN, our colors are in our DNA! We celebrate the diversity and inclusivity of our team. This Pride Month, we honor the voices of our LGBTQ+ colleagues, like Sam Hey, highlighting the integral roles we all play in the Pride initiative.

#PrideMonth #LGBTQ #QIAversity #Diversity #Inclusion

When it comes to work, Anna Kubiak’s biggest challenge was transitioning from a specialist to a managerial role, as it required her to develop new skills and adapt to a broader scope of responsibilities. However, she has enjoyed every step of the journey.
 
“Being a leader allows me to develop myself by developing others. It’s amazing to grow with the company and see others grow alongside it. I also appreciate the independence QIAGEN gives me, empowering and trusting me,” she says, highlighting that career development at QIAGEN is accessible to everyone, regardless of gender.
 
What does she like most about her job? “Working at QIAGEN means being part of a company where diversity and inclusion are not just buzzwords, but truly embedded in our company DNA. Here, people can be their true selves, and not only does the company respect this, but the people are also incredibly supportive and welcoming.”

Did you know #tuberculosis (#TB) has reclaimed the title of the world’s deadliest infectious disease from COVID-19? Our CEO, Thierry BERNARD, stresses the urgent need for global coordination and investment in TB control measures to eradicate the disease and prevent future outbreaks. Learn more 👉 https://lnkd.in/evHx5AQr

😎 The main difference between nanoplate dPCR and droplet digital PCR (ddPCR) is the partitioning approach. In ddPCR, the partitioning is achieved using a droplet generator, in nanoplate dPCR, the partitioning is achieved using a digital PCR plate.

🤔 Want to learn more? Read about the differences between nanoplate dPCR vs ddPCR here: https://lnkd.in/gsDyEUJF

👍 Here's why you should choose nanoplate dPCR over ddPCR:

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	1.30B -	1.34B 3.29%	1.28B 4.74%	1.34B 4.45%	1.42B 5.95%	1.50B 5.95%	1.53B 1.64%	1.87B 22.53%	2.25B 20.39%	2.14B 4.89%	1.97B 8.23%
cost of revenue	486.49M -	479.84M 1.37%	454.61M 5.26%	493.34M 8.52%	494.98M 0.33%	500.89M 1.19%	521.16M 4.05%	642.54M 23.29%	800.84M 24.64%	756.96M 5.48%	742.39M 1.92%
gross profit	815.49M -	864.94M 6.06%	826.38M 4.46%	844.65M 2.21%	922.56M 9.22%	1.00B 8.50%	1.01B 0.43%	1.23B 22.14%	1.45B 18.16%	1.38B 4.57%	1.22B 11.67%
selling and marketing expenses	371.52M -	376.87M 1.44%	360.96M 4.22%	401.35M 11.19%	375.56M 6.43%	392.28M 4.45%	391.91M 0.10%	434.16M 10.78%	456.39M 5.12%	474.22M 3.91%	459.91M 3.02%
general and administrative expenses	199.07M -	126.55M 36.43%	103.87M 17.92%	129.25M 24.43%	200.10M 54.82%	141.21M 29.43%	112.26M 20.50%	110.15M 1.88%	128.08M 16.27%	129.72M 1.29%	119.25M 8.07%
selling general and administrative expenses	570.60M -	503.42M 11.77%	464.84M 7.66%	530.60M 14.15%	575.66M 8.49%	533.50M 7.32%	504.17M 5.50%	544.31M 7.96%	584.47M 7.38%	603.95M 3.33%	579.17M 4.10%
research and development expenses	146.07M -	163.63M 12.02%	147.18M 10.05%	176.13M 19.67%	154.08M 12.52%	161.85M 5.04%	157.45M 2.72%	139.06M 11.68%	189.96M 36.61%	189.86M 0.06%	198.51M 4.56%
other expenses	2.59M -	-6.94M 367.77%	-10.55M 52.09%	-9.67M 8.33%	-4K 99.96%	5.60M 140,050%	29.97M 435.42%	-430K 101.43%	18.54M 4,412.09%	14.53M 21.63%	-5.71M 139.30%
cost and expenses	1.24B -	1.18B 4.42%	1.11B 6.64%	1.24B 12.11%	1.26B 2.01%	1.24B 2.28%	1.21B 1.82%	1.33B 9.30%	1.59B 20.24%	1.57B 1.79%	1.52B 2.89%
operating expenses	752.16M -	704.12M 6.39%	650.68M 7.59%	745.83M 14.62%	769.14M 3.13%	734.38M 4.52%	691.59M 5.83%	682.94M 1.25%	792.97M 16.11%	808.34M 1.94%	777.68M 3.79%
interest expense	30.88M -	39.33M 27.36%	37.40M 4.92%	39.02M 4.35%	49.69M 27.33%	67.29M 35.44%	74.19M 10.24%	73.00M 1.59%	54.48M 25.38%	58.36M 7.12%	53.41M 8.48%
ebitda	103.72M -	194.91M 87.93%	361.37M 85.40%	308.99M 14.50%	380.51M 23.15%	499.47M 31.26%	567.68M 13.66%	764.87M 34.74%	923.00M 20.67%	824.12M 10.71%	650.58M 21.06%
operating income	63.33M -	160.82M 153.94%	175.69M 9.25%	98.83M 43.75%	153.42M 55.24%	266.58M 73.76%	336.22M 26.12%	554.90M 65.04%	630.08M 13.55%	531.46M 15.65%	445.25M 16.22%
depreciation and amortization	35.49M -	37.07M 4.44%	191.47M 416.52%	213.06M 11.27%	216.45M 1.59%	206.44M 4.63%	231.46M 12.12%	209.97M 9.28%	292.92M 39.50%	292.66M 0.09%	205.34M 29.84%
total other income expenses net	2.59M -	-6.94M 367.77%	-10.55M 52.09%	-9.67M 8.33%	-4K 99.96%	5.60M 140,050%	-413.99M 7,495.39%	-399.97M 3.39%	-4.25M 98.94%	-18.86M 343.64%	-15.44M 18.14%
income before tax	37.34M -	118.51M 217.41%	132.50M 11.80%	56.91M 57.05%	114.38M 100.98%	225.74M 97.37%	-77.78M 134.45%	154.93M 299.20%	625.83M 303.95%	512.60M 18.09%	429.81M 16.15%
income tax expense	-31.76M -	1.31M 104.13%	5.64M 329.95%	-23.39M 514.73%	73.98M 416.23%	35.36M 52.21%	-36.32M 202.73%	81.29M 323.80%	113.23M 39.30%	89.39M 21.06%	88.51M 0.99%
net income	69.07M -	116.63M 68.86%	127.10M 8.98%	80.40M 36.74%	40.39M 49.76%	190.38M 371.31%	-41.45M 121.77%	73.64M 277.64%	512.60M 596.09%	423.21M 17.44%	341.30M 19.35%
weighted average shs out	225.23M -	223.43M 0.80%	224.38M 0.42%	225.87M 0.67%	228.07M 0.97%	225.51M 1.12%	227.75M 0.99%	228.43M 0.30%	227.07M 0.59%	227.72M 0.28%	221.30M 2.82%
weighted average shs out dil	233.21M -	232.59M 0.26%	228.37M 1.81%	230.14M 0.77%	233.01M 1.25%	233.46M 0.19%	232.42M 0.44%	234.21M 0.77%	232.03M 0.93%	230.14M 0.82%	223.70M 2.80%
eps	0.31 -	0.52 67.74%	0.57 9.62%	0.36 36.84%	0.18 50%	0.84 366.67%	-0.18 121.43%	0.32 277.78%	2.26 606.25%	1.86 17.70%	1.54 17.20%
epsdiluted	0.30 -	0.50 66.67%	0.56 12.00%	0.35 37.50%	0.17 51.43%	0.82 382.35%	-0.18 121.95%	0.31 272.22%	2.21 612.90%	1.84 16.74%	1.53 16.85%

COM:QIAGEN

QIAGEN

Last Close

42.33

22/11 21:00

Market Cap

9.10B

Beta: -

Volume Today

679.93K

Avg: -

Preview